1(2H)-Isoquinolinone, 3,4-dihydro-8-methoxy-6-[7-[2-(4-morpholinyl)ethoxy]imidazo[1,2-a]pyridin-3-yl]-2-(2,2,2-trifluoroethyl)- manufacturers
- GLPG3970
-
- $60.00
-
2026-08-20
- CAS:2403733-82-2
- Purity: 99.63%
- Supply Ability: 10g
|
| | 1(2H)-Isoquinolinone, 3,4-dihydro-8-methoxy-6-[7-[2-(4-morpholinyl)ethoxy]imidazo[1,2-a]pyridin-3-yl]-2-(2,2,2-trifluoroethyl)- Basic information |
| Product Name: | 1(2H)-Isoquinolinone, 3,4-dihydro-8-methoxy-6-[7-[2-(4-morpholinyl)ethoxy]imidazo[1,2-a]pyridin-3-yl]-2-(2,2,2-trifluoroethyl)- | | Synonyms: | 1(2H)-Isoquinolinone, 3,4-dihydro-8-methoxy-6-[7-[2-(4-morpholinyl)ethoxy]imidazo[1,2-a]pyridin-3-yl]-2-(2,2,2-trifluoroethyl)-;8-methoxy-6-(7-(2-morpholinoethoxy)imidazo[1,2-a]pyridin-3-yl)-2-(2,2,2-trifluoroethyl)-3,4-dihydroisoquinolin-1(2H)-one;8-methoxy-6-{7-[2-(morpholin-4-yl)ethoxy]imidazo[1,2-a]pyridin-3-yl}-2-(2,2,2-trifluoroethyl)-3,4-dihydroisoquinolin-1-one - [AC78220] | | CAS: | 2403733-82-2 | | MF: | C25H27F3N4O4 | | MW: | 504.5 | | EINECS: | | | Product Categories: | | | Mol File: | 2403733-82-2.mol | ![1(2H)-Isoquinolinone, 3,4-dihydro-8-methoxy-6-[7-[2-(4-morpholinyl)ethoxy]imidazo[1,2-a]pyridin-3-yl]-2-(2,2,2-trifluoroethyl)- Structure](CAS/20210305/GIF/2403733-82-2.gif) |
| | 1(2H)-Isoquinolinone, 3,4-dihydro-8-methoxy-6-[7-[2-(4-morpholinyl)ethoxy]imidazo[1,2-a]pyridin-3-yl]-2-(2,2,2-trifluoroethyl)- Chemical Properties |
| density | 1.40±0.1 g/cm3(Predicted) | | pka | 5.87±0.10(Predicted) | | form | Solid | | color | White to off-white |
| | 1(2H)-Isoquinolinone, 3,4-dihydro-8-methoxy-6-[7-[2-(4-morpholinyl)ethoxy]imidazo[1,2-a]pyridin-3-yl]-2-(2,2,2-trifluoroethyl)- Usage And Synthesis |
| Uses | GLPG3970 (compound 88) is a first-in-class SIK2/SIK3 inhibitor. GLPG3970 can be used for the research of inflammation and autoimmune disease[1]. | | in vivo | GLPG3970 (10 mg/kg; oral administration; twice daily for 5 consecutive days) decreases the ear thickness of murine models of psoriatic-like epidermal hyperplasia induced by intradermal injections of IL-23[1].
GLPG3970 (60 mg/kg; oral administration; twice daily until mice are sacrificed) shows better clinical manifestations compared to vehicle groups in murine collagen-antibody induced arthritis model (CAIA)[1].
GLPG3970 (30 mg/kg; oral administration; twice daily for 7 consecutive days) reduces disease activity index ompared to vehicle groups in mice T cell transfer model[1]. | | References | [1] DESROY N, et al. NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES. WO/2019/238424. 2019. |
| | 1(2H)-Isoquinolinone, 3,4-dihydro-8-methoxy-6-[7-[2-(4-morpholinyl)ethoxy]imidazo[1,2-a]pyridin-3-yl]-2-(2,2,2-trifluoroethyl)- Preparation Products And Raw materials |
|